Editorial: Adiponectin and Metabolic Syndrome Prevention

In recent years, adiponectin (apn), a novel adipocytokine, has attracted the scientists attention. low circulatory concentration of this protein is observed in obese patients and patients with type 2 diabetes and metabolic syndrome. moreover, through its antiatherogenic and anti-inflammatory effects, apn plays a protective role against the development of metabolic disorders. metabolic syndrome (mets) is a collection of obesityassociated disorders and is very common in different populations. its prevalence in iran is reported at 34.7% to 41.6% depending on the different diagnostic criteria in rural and urban area. higher prevalence has also been reported in the particular populations; for example, in people older than 60 years old in west of iran the prevalence was reported at 44.7%. an important issue in this